<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392011</url>
  </required_header>
  <id_info>
    <org_study_id>17823</org_study_id>
    <secondary_id>U54AT008909</secondary_id>
    <nct_id>NCT04392011</nct_id>
  </id_info>
  <brief_title>Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product</brief_title>
  <official_title>Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kratom is a botanical natural product that has opioid-like effects. Kratom is commonly used
      to self-treat withdrawal symptoms associated with opioid addiction, as well as pain. Kratom
      products include pills, extracts, and powders, most of which contain two primary psychoactive
      constituents: mitragynine and 7-hydroxymitragynine. Preliminary data from the investigator's
      laboratory has shown that these two constituents and extracts made from commercially
      available kratom products are strong inhibitors of the drug metabolizing enzymes cytochrome
      P450 (CYP) 2D6 and CYP3A4. These enzymes are responsible for metabolizing more than 50% of
      marketed drugs, including several opioids, benzodiazepines, and antidepressants. Thus,
      co-consumption of kratom products with drugs metabolized by CYP2D6 and CYP3A4 could increase
      the risk of serious adverse effects. The effects of a well-characterized kratom product on
      CYP2D6 and CYP3A4 activity will be assessed in healthy volunteers using a 'cocktail' approach
      consisting of the validated probe drugs dextromethorphan and midazolam. Results will (1)
      provide useful information regarding risks associated with co-consuming kratom with opioids
      and other CYP2D6 and CYP3A4 drug substrates and (2) inform the design of future kratom-drug
      interactions studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many patient groups often supplement their drug regimens with herbal and other natural
      products (NPs), raising concern for adverse NP-drug interactions. Due to a lack of rigorous
      guidelines for assessing the risk of NP-drug interactions, the NIH-funded Center of
      Excellence for Natural Product-Drug Interaction Research (NaPDI Center) was established to
      facilitate the identification, evaluation, and dissemination of potentially clinically
      relevant pharmacokinetic NP-drug interactions.Kratom is one of four high priority NPs
      selected by the NaPDI Center for rigorous study of drug interaction potential.

      Kratom (Mitragyna speciosa) is a tree native to Southeast Asia that produces constituents
      with opioid-like effects. Oral supplements made from the leaves are readily available in the
      United States and are used for several purported medicinal benefits, such as pain relief,
      treatment of post-traumatic stress disorder, and management of opioid addiction. Two
      psychoactive constituents of the kratom leaf, mitragynine and 7- hydroxymitragynine, are
      believed to contribute to these effects.

      Calls to poison control centers in the United States involving kratom exposures increased
      from 2011 to 2017 by 52-fold. More than one-third of the calls reported combined use of
      kratom with other substances, including opioids and benzodiazepines. In October 2017, the
      opioid crisis was declared a public health emergency. Many opioids are metabolized by the
      major drug metabolizing enzymes CYP2D6 and CYP3A4, which have been shown to be inhibited by
      an extract prepared from a well-characterized kratom product and purified major kratom
      constituents, including mitragynine and 7-hydroxymitragynine. As such, co-consuming kratom
      with these opioids could increase the risk of serious adverse effects via inhibition of
      opioid metabolism, notably respiratory depression, the primary cause of death from opioid
      overdose.

      The purpose of this study is to assess the effects of a well-characterized kratom product on
      CYP2D6 and CYP3A4 activity in healthy volunteers using a cocktail approach consisting of the
      validated probe drugs dextromethorphan and midazolam. The primary objective is to evaluate
      the potential for a pharmacokinetic kratom-drug interaction with midazolam, a 'probe' drug
      for CYP3A4, when administered to participants previously exposed to kratom. Secondary
      objectives are to evaluate the pharmacokinetics of kratom constituents and the effect of
      kratom on the pharmacokinetics of dextromethorphan, a probe drug for CYP2D6.

      Results will be used to develop physiologically-based pharmacokinetic (PBPK) models to
      predict the likelihood and magnitude of kratom-drug interactions, including those involving
      opioids. These PBPK models could be adapted to other CYP2D6 and CYP3A4 drug substrates with
      high abuse potential (e.g., benzodiazepines and 'Z-drugs') and used to inform the design of
      future kratom-drug interactions studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Midazolam area under the concentration vs. time curve (AUC) ratio (treatment/control)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Ratio of the area under the plasma concentration time curve (AUC) of midazolam in the presence to absence of kratom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dextromethorphan area under the concentration vs. time curve (AUC) ratio (treatment/control)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Ratio of the area under the plasma concentration time curve (AUC) of dextromethorphan in the presence to absence of kratom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kratom constitutent area under the concentration vs. time curve (AUC)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Area under the concentration vs. time curve (AUC) of kratom constituents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Midazolam and dextromethorphan Cmax ratio (treatment/control)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Ratio of the maximum plasma concentration (Cmax) of midazolam or dextromethorphan in the presence to absence of kratom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kratom constituent Cmax</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Maximum plasma concentration of kratom constituents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Midazolam, dextromethorphan, and kratom constituent half-life</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Time to reach one-half of the concentration of midazolam, dextromethorphan, and kratom constituent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Midazolam, dextromethorphan, and kratom constituent Tmax</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Time to reach maximum plasma concentration (Cmax) of midazolam, dextromethorphan, and kratom constituent.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Interaction Drug Food</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six non-naive* subjects (3 men, 3 women) will be administered a single low dose of a well-characterized kratom product (2 g) by mouth as a tea. These subjects may or may not choose to participate in Arms 2a and 2b. For subjects who will participate in Arms 2a and 2b, a washout period of 7 days will separate Arm 1 and Arm 2. Plasma will be collected from 0-120 hours and during the washout period. Urine will be collected from 0-120 hours.
*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 is divided into Arms 2a and 2b. Twelve non-naive subjects (6 men and 6 women) will participate in Arm 2a. Subjects who participate in this study arm will be administered an oral probe drug cocktail of dextromethorphan HBr (2 x 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-24 hours. Urine will be collected from 0-24 hours. A washout period of 7 days will separate Arms 2a and 2b.
For Arm 2b, the same 12 subjects will be administered a combination of a well-characterized kratom product (2 g) by mouth as a tea with an oral probe drug cocktail consisting of dextromethorphan HBr (2, 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-12 hours and during a midpoint collection within 5 days of the 24-hour blood collection. Urine will be collected from 0-24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam HCl</intervention_name>
    <description>Oral syrup, 2 mg/mL</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan HBr</intervention_name>
    <description>Oral liquid capsules, 15 mg</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Kratom</intervention_name>
    <description>Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not taking any medications (prescription and non-prescription) or dietary/herbal
             supplements known to alter the pharmacokinetics of either study drug or kratom
             constituents

          -  Willing to abstain from consuming dietary/herbal supplements, including kratom, and
             citrus juices for several weeks

          -  Willing to abstain from consuming caffeinated beverages or other caffeine-containing
             products the evening before and morning of the first day of a study arm

          -  Willing to abstain from consuming any alcoholic beverages for one day prior to any
             study day, during the 14-hour inpatient days, and for the 5 and/or 1 outpatient
             visit(s) following 14-hour visit

          -  Willing to use an acceptable method of contraception that does not include oral
             contraceptive pills or patches (such as abstinence, copper IUD, condom)

          -  Have the time to participate

          -  Are non-na√Øve kratom users (intermittent users who are not trying to quit but willing
             to abstain for several weeks)

          -  Carry a CYP2D6 genotype designated as having an intermediate, extensive, or
             ultra-extensive metabolizer phenotype

          -  Written informed consent (and assent when applicable) obtained from subject or
             subject's legal representative and ability for the subject to comply with the
             requirements of the study

        Exclusion Criteria:

          -  Men and women under the age of 18 or over the age of 55

          -  Unwilling to abstain from kratom for several weeks

          -  Any current major illness or chronic illness such as (but not limited to) kidney
             disease, hepatic disease, diabetes mellitus, hypertension, coronary artery disease,
             chronic obstructive pulmonary disease, cancer, or HIV/AIDS

          -  History of anemia or any other significant hematologic disorder

          -  History of drug or alcohol addiction or major psychiatric illness

          -  A need for chronic opioid analgesics

          -  Use of opioid analgesics 3 weeks prior to initiation of the study

          -  An imminent likely need for opioid analgesics (e.g., planned dental or surgical
             procedure)

          -  Female and pregnant or nursing

          -  Have a history of allergy to dextromethorphan, midazolam, or related drugs

          -  Have a history of intolerance or allergy to kratom or opioids

          -  Taking concomitant medications, both prescription and non-prescription (including
             dietary supplements/herbal products), known to alter the pharmacokinetics of either
             study drug or kratom constituents

          -  Carry a CYP2D6 genotype designated as having a poor metabolizer phenotype

          -  Presence of a condition or abnormality that, in the opinion of the Investigator, would
             compromise the safety of the patient or the quality of the data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary F Paine, Ph.D., R.Ph</last_name>
    <phone>509-358-7759</phone>
    <email>mary.paine@wsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deena Hadi, B.S.</last_name>
    <phone>509-368-6692</phone>
    <email>deena.hadi@wsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington State University College of Pharmacy and Pharmaceutical Sciences</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary F Paine, PhD, RPh</last_name>
      <phone>509-358-7759</phone>
      <email>mary.paine@wsu.edu</email>
    </contact>
    <investigator>
      <last_name>Mary F Paine, PhD, RPh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Layton, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John White, PharmD, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to United States poison control centers: 2011-2017. Clin Toxicol (Phila). 2019 Oct;57(10):847-854. doi: 10.1080/15563650.2019.1569236. Epub 2019 Feb 20.</citation>
    <PMID>30786220</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Kratom</keyword>
  <keyword>Mitragynine</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Dextromethorphan</keyword>
  <keyword>Natural product</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

